Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26475 | 0.93 | ALDH1A1 (0.35) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL599115 | 0.91 | SLC18A2 (0.33) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL25920 | 0.90 | ALDH1A1 (0.37) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL599081 | 0.90 | ALDH1A1 (0.39) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL26218 | 0.89 | SLC18A2 (0.36) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL598340 | 0.87 | ALDH1A1 (0.35) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL600132 | 0.84 | ALDH1A1 (0.36) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL25397 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL25400 | 0.83 | LMNA (0.38) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL2690074 | 0.83 | CTSL (0.40) | ALDH1A1HPGDCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086530-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | Xenoport, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | XENOPORT, INC. | 2008-08-07 | — | — | US | claimed |
| WO-2008060572-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | XENOPORT, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-7186855-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | claimed |
| US-8168623-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | XENOPORT INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2275401-A1 | Crystalline 1-{[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid | XenoPort, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100267946-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7790708-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070010453-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | disclosed |
| WO-2005089872-A2 | TREATMENT OF LOCAL PAIN | XENOPORT, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209319-A1 | Treatment of local pain | XENOPORT, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267946-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885CYP1A2 135/4885TSHR 2583/4885 |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | GABRB1, GABBR1, GABRB2 | ALDH1A1 148/4885CYP1A2 648/4885TSHR 2185/4885 |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | GABBR2, GABBR1, GABRB2 | ALDH1A1 2011/4885CYP1A2 678/4885TSHR 1300/4885 |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | ALDH1A1 495/4885CYP1A2 1323/4885TSHR 2118/4885 |
| US-20070010453-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885CYP1A2 135/4885TSHR 2583/4885 |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | GABRB1, GABBR1, GABRB3 | ALDH1A1 2545/4885CYP1A2 819/4885TSHR 3350/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885CYP1A2 135/4885TSHR 2583/4885 |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | ALDH1A1 495/4885CYP1A2 1323/4885TSHR 2118/4885 |
| US-20050209319-A1 | Treatment of local pain | GABBR1, GABBR2, GABRB2 | ALDH1A1 1056/4885CYP1A2 826/4885TSHR 4621/4885 |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | GABBR1, GABRE, GABRB2 | ALDH1A1 764/4885CYP1A2 243/4885TSHR 4693/4885 |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | GABBR1, GABBR2, GABRB3 | ALDH1A1 445/4885CYP1A2 335/4885TSHR 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.